0001725160-24-000026.txt : 20240205 0001725160-24-000026.hdr.sgml : 20240205 20240205191129 ACCESSION NUMBER: 0001725160-24-000026 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240201 FILED AS OF DATE: 20240205 DATE AS OF CHANGE: 20240205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blackwell Kimberly CENTRAL INDEX KEY: 0001816465 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39263 FILM NUMBER: 24597514 MAIL ADDRESS: STREET 1: C/O ZENTALIS PHARMACEUTICALS, LLC STREET 2: 530 SEVENTH AVENUE, SUITE 2201 CITY: NEW YORK STATE: NY ZIP: 10018 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001725160 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 823607803 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1359 BROADWAY, SUITE 801 CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: (212) 433-3791 MAIL ADDRESS: STREET 1: 1359 BROADWAY, SUITE 801 CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC DATE OF NAME CHANGE: 20200107 FORMER COMPANY: FORMER CONFORMED NAME: Zeno Pharma, LLC DATE OF NAME CHANGE: 20171212 4 1 wk-form4_1707178279.xml FORM 4 X0508 4 2024-02-01 0 0001725160 Zentalis Pharmaceuticals, Inc. ZNTL 0001816465 Blackwell Kimberly C/O ZENTALIS PHARMACEUTICALS, INC. 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 1 1 0 0 Chief Executive Officer 0 Common Stock 2024-02-01 4 A 0 250000 0 A 504800 D Common Stock 2024-02-01 4 F 0 20655 11.69 D 484145 D Stock Option (Right to Buy) 11.69 2024-02-01 4 A 0 250000 0 A 2034-01-31 Common Stock 250000 250000 D Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer. Shares automatically withheld to satisfy tax obligations upon the vesting of restricted stock units previously granted to the Reporting Person. The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. By: /s/ Melissa B. Epperly, Attorney-in-Fact for Kimberly Blackwell 2024-02-05